Neuroprotection · Nootropic

Cerebrolysin

Also known as: Cerebrolysin concentrate, FPF-1070

A complex mixture of peptide fragments and amino acids derived from porcine brain tissue, used clinically in many countries for stroke and dementia and characterized as a polypeptide drug rather than a single defined peptide.

Sign in to add to watchlist

Evidence strength

Strength of human clinical evidence — A (strongest) to D (mostly preclinical). This reflects research maturity, not safety or suitability.

CMixed or Limited Human Evidence

Vial Theory provides educational research summaries only. Content is not medical advice, diagnosis, treatment, dosing guidance, or individualized suitability screening. Regulatory status can change over time and varies by jurisdiction.

Key Takeaways

  • ›Cerebrolysin is a standardized mixture of peptides and amino acids from porcine brain tissue, not a single peptide.
  • ›It is approved and used for stroke and dementia in many countries but is not FDA-approved in the US.
  • ›Clinical evidence shows modest and inconsistent benefits, not large effects.
  • ›Its complex, animal-derived nature raises distinct quality and consistency considerations.
  • ›Using it for general cognitive enhancement exceeds the evidence. Speak with a licensed healthcare professional.

What It Is

Cerebrolysin is not a single defined peptide but rather a concentrate of low-molecular-weight peptide fragments and free amino acids derived from controlled enzymatic breakdown of purified porcine brain tissue. The active components include short peptides in the molecular weight range below approximately 10 kDa, along with constituent amino acids. The proprietary manufacturing process by EVER Neuro Pharma (Austria) standardizes the composition to a defined specification.

Mechanistically, cerebrolysin is characterized as having neurotrophic-factor-like activity, with effects on neuronal survival, neuroplasticity, and synaptogenesis in preclinical models. The proposed framework is that the compound mimics the action of endogenous neurotrophic factors (NGF, BDNF, and others) through its peptide components, though the precise contributions of individual components are not fully characterized. The compound is administered intravenously or intramuscularly in clinical use.

Unlock the full Cerebrolysin research report

Vial+ opens the mechanism breakdown, evidence graphs, potential benefits, safety considerations, regulatory status, a plain-language explainer, and 4 cited sources.

Get Vial+ — $20 one-time

Lifetime access · the community forum stays free.

Disclaimer: This content is for educational and research purposes only and is not medical advice. Always consult a licensed healthcare professional before making health-related decisions.